
Jay Spiegel, MD, discusses what led to the initiation of a phase 2 study evaluating CRG-022 in patients with relapsed/refractory large B-cell lymphoma following treatment with CD19-directed CAR T-cell therapy.

Your AI-Trained Oncology Knowledge Connection!

Jay Spiegel, MD, is a transplant and cellular therapy physician at the University of Miami Health.